Chronic kidney disease undergoing hemodialysis
Conditions
Interventions
Hemodiafiltration treatment
Post-HDF-PMMA (high flow): Mode
post-dilution OL-HDF, Hemodiafilter
Filtrailzer HDF, Dialysate 450 mL/min, Filtration 50 mL/min, Quantity of blood 250 mL/min
Post-HDF-PMMA (low flow): Mode
Filtrailzer HDF, Dialysate 470 mL/min, Filtration 30 mL/min, Quantity of blood 250 mL/min
Pre-HDF-PS: Mode
pre-dilution OL-HDF, Hemodiafilter
NVF-21M, Dialysate 300 mL/min, Filtration 200 mL/min, Quantity of blood 250 mL/min
Study schedule
Visit 1, 2, 3, 5, 6: Pre-HDF-PS
Visit 4: Post-HDF-PMMA (low flow)
Visit 7: Post-HDF-PMMA (high flow)
Renal dialysis
PMMA, adsorption, hemodiafiltration
Sponsors
Yamamoto Suguru
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet the all inclusion criteria as bellow, 1. Patients who can obtain written informed consent to participate in this study based on their free will. 2. Patients whose age is more than 18 years old. 3. Patients undergoing pre-dilution hemodiafiltration with NVF-21M hemodiafilter. 4. Patients whose vascular access can keep blood flow more than 250 mL/minute 5. Patients who do not have redisual kidney function.
Exclusion criteria
Exclusion criteria: Patients who meet any exlusion criteria as bellow. 1. Patients who participate other clinical studies. 2. Patients who are pregnant or want pregnancy. 3. Patients with blood hemoglobin level <10 g/dL. 4. Patients with severe heart failure. 5. Patients who needed to change quantity of blood during dialysis treatment owing to worse of circulation in recent three sessions. 6. Patients that the investigators decide inappropreate to join the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clearance of alfa 1-microglobulin at 60 min after start of dialysis session | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Effect Removal rate and clearance of Alfa 1-microglobulin (except for the clearance at 60 minutes of treatment), Beta 2-microglobulin,urine nitrogen, cleatinine, phosphate, uric acid, interleukin 6, tumor necrosis factor alfa. 2. Safety Change of blood pressure and pulse rate during hemodiafiltration treatment. Transmembrane pressure during hemodiafiltration treatment. Incidence of any diseases during the study period. Mechanical troubles during hemodiafiltration treatment. | — |
Contacts
Public ContactSuguru Yamamoto
Niigata University Medical and Dental Hospital
Outcome results
None listed